Business Information
The group's principal activity is to market brand name prescription drugs. The group intends to develop new patentable formulations, use new delivery methods and seek regulatory approval for new indications of existing drugs. The main products of the group include nisoldipine, nitrolingual pumpspray, prenate advance and prenate gt, ponstel, furadantin, tanafed dp and tanafed dmx, robinul and robinul forte. The group sells its products to cardiologists, obstetricians and gynecologists, pediatricians, gastroenterologists and primary care physicians. The products of the group are sold under the tradenames mescolor, protuss, zoto-hc (and an associated design), defen, zebutal, prenate gt and furadantin.
|
|
Name |
Title
|
Email
|
| Pierre Lapalme | Chmn. | Available | | Darrell Borne | Exec. VP, CFO, Sec., Treasurer | Available | | Edward Schutter | Exec. VP, Chief Commercial Officer | Available | | Larry Dillaha | Chief Medical Officer, Exec. VP | Available | | Leslie Zacks | Exec. VP - Legal, Compliance | Available
|
|
|
Year |
Sales |
Net Income |
| 2006 | 293,181 | 45,244 | | 2005 | 216,358 | 39,209 | | 2004 | 151,967 | 26,554
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
